AP3B2

Across TCGA pan-cancer cohorts, AP3B2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP3B2 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher AP3B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3B2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

ACC, ESCA, and COAD are the cancer types where AP3B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
ESCA	DFS	Median	All	0.164	0.535	.010	12	view →
COAD	OS	Median	All	1.000	0.518	.024	4	view →
BLCA	OS	Median	III,IV	0.174	0.579	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AP3B2–ACC (DFS)

Open the ACC breakdown →